# Balestier

> Balestier is a VC fund backing Health Care, Medical Device and Wellness. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Apr 2022
- Lead investor: 0%
- Last updated: Aug 2026

Balestier is a VC fund focused on Health Care and Medical Device. A Singaporean family fund.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Medical Device | 2 | 67% |
| Wellness | 1 | 33% |
| Emergency Medicine | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 33% |
| Series C | 1 | 33% |
| Series D | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LimFlow SA | LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularizationefforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. | $39.3M | Series D | Apr 05, 2022 |  |
| Cagent Vascular | Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. | $11.9M | Series B | Jul 12, 2018 |  |
| LimFlow SA | LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularizationefforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. | $28.7M | Series C | Apr 16, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 3 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Ben Franklin Technology Partners](https://shizune.co/investors/profile/ben-franklin-technology-partners) — VC Fund, 1 deal together
- [French sovereign investment bank](https://shizune.co/investors/profile/french-sovereign-investment-bank) — VC Fund, 1 deal together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 1 deal together
- [Soleus Capital](https://shizune.co/investors/profile/soleus-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Balestier invest in?

Balestier invests primarily in Health Care, Medical Device and Wellness startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Balestier last invest?

The most recent investment recorded for Balestier closed in Apr 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co